



MILLENNIUM
Peptides for Health

ARA 290 (Cibinetide)

Clinical Overview for Neuroimmune, Metabolic, and Cardiovascular Restoration

ARA 290: Clinical Overview for Neuroimmune, Metabolic, and Cardiovascular Restoration.

Mark L. Gordon, MD. Peptides for Health Series (2025). Youtube.com/@markl.gordon5856

Overview

ARA 290, also known by its developmental name *Cibinetide*, is a next-generation, 11-amino acid synthetic peptide derived from the tertiary structure of erythropoietin (EPO). Unlike its parent molecule, ARA 290 has been specifically engineered to bypass the classical erythropoietic pathway and instead target the **innate repair receptor (IRR)**—a specialized heteromeric receptor complex formed transiently in damaged or stressed tissues. This precision targeting allows ARA 290 to preserve the regenerative, anti-inflammatory, and cytoprotective properties of EPO while eliminating its erythropoietic and pro-thrombotic risks, making it a uniquely safe and focused therapeutic agent.

Clinically, ARA 290 is emerging as a powerful neuromodulatory and tissue-reparative peptide with a broad therapeutic spectrum. It is currently under active investigation across a range of disorders involving inflammation, ischemia, and neurodegeneration. These include **type 2 diabetes complicated by small fiber neuropathy, sarcoidosis-induced nerve fiber loss, traumatic brain injury, ischemic heart disease**, and other conditions marked by immune dysregulation and tissue damage. Early-phase human trials and robust preclinical studies have demonstrated its ability to restore neural architecture, modulate immune activity, enhance metabolic balance, and promote vascular healing—all without the hematologic liabilities associated with EPO.

ARA 290 represents a paradigm shift in peptide-based medicine, offering a multifaceted approach to tissue repair that is not only disease-modifying but also well tolerated. Its systemic impact on neuroimmune communication, mitochondrial function, and vascular integrity places it at the intersection of neurology, cardiology, endocrinology, and immunology—defining it as a next-generation therapeutic for clinicians seeking innovative solutions to complex, chronic diseases.

Pharmacodynamics and Mechanism of Action

ARA 290 achieves its multifaceted therapeutic effects by selectively engaging the **innate repair receptor (IRR)**, a transiently expressed heteromeric receptor formed by the erythropoietin receptor (EPOR) in combination with the β -common receptor subunit CD131. This receptor complex is uniquely upregulated in response to cellular stress, injury, or metabolic dysfunction, and is absent under normal physiological conditions—making it an ideal pharmacological target for site-specific tissue repair and inflammation resolution.

Upon binding to the IRR, ARA 290 initiates a cascade of downstream signaling pathways that orchestrate potent anti-inflammatory, neuroregenerative, metabolic, and cardioprotective responses. At the immunological level, ARA 290 suppresses key pro-inflammatory cytokines such as tumor necrosis factor- α (TNF- α) and interleukin-1 beta (IL-1 β), while simultaneously downregulating microglial activation in the central nervous system, effectively blunting neuroinflammation and its downstream sequelae.

In neural tissue, ARA 290 supports the regeneration of damaged fibers by stimulating the growth of both small unmyelinated and lightly myelinated nerve fibers. Clinical evidence, including corneal confocal microscopy studies, has demonstrated increased **corneal nerve fiber density (CNFD)** following treatment in both diabetic and sarcoidosis-associated small fiber neuropathy—an objective marker of its neurorestorative efficacy.

Metabolically, ARA 290 improves systemic insulin sensitivity, resulting in reductions in hemoglobin A1c (HbA1c), serum triglycerides, and favorable modulation of LDL/HDL cholesterol ratios in individuals with type 2 diabetes. These metabolic benefits are further amplified by the peptide's effects on mitochondrial

function, as it promotes mitochondrial biogenesis and enhances glucose uptake and utilization in skeletal muscle, thereby supporting overall energy metabolism and tissue resilience.

In the cardiovascular system, ARA 290 has shown strong potential in mitigating ischemic injury by reducing infarct size and promoting favorable myocardial remodeling following myocardial infarction. These effects are attributed not only to its anti-inflammatory profile but also to improved endothelial integrity and perfusion within the affected myocardial tissue.

Taken together, the mechanism of ARA 290 offers a comprehensive therapeutic platform—targeting the core pathophysiological processes of inflammation, oxidative stress, neural degeneration, mitochondrial dysfunction, and ischemic damage—without invoking the hematologic complications historically associated with erythropoietin analogs.

Clinical Applications and Benefits

ARA 290 demonstrates broad therapeutic potential across neurological, metabolic, and cardiovascular domains, making it a uniquely integrative intervention for systemic repair and functional restoration.

Within the neurological and neuroimmune systems, ARA 290 has shown exceptional promise in the treatment of small fiber neuropathy (SFN)—a condition marked by the degeneration of peripheral sensory and autonomic nerve fibers. Clinical trials have demonstrated that ARA 290 not only alleviates debilitating sensory symptoms such as burning, tingling, and allodynia, but also promotes structural nerve regeneration, as evidenced by measurable increases in corneal nerve fiber density (CNFD). In contrast to conventional neuropathic pain medications that merely mask symptoms, ARA 290 exerts disease-modifying effects, restoring underlying nerve integrity by suppressing neuroinflammation and stimulating fiber regrowth.

Its benefits extend to neuropathic pain syndromes, where long-term relief has been observed without reliance on analgesic pathways. Rather than acting through opioid or sodium channel blockade, ARA 290 reduces the molecular drivers of pain by modulating immune responses and neural inflammation. Similarly, in cases of traumatic brain injury (TBI), ARA 290 has demonstrated neuroprotective properties—reducing post-injury inflammation, preserving neuronal architecture, and minimizing secondary neurologic deficits.

Metabolically, ARA 290 has been shown to improve glycemic control and lipid profiles in individuals with type 2 diabetes. It reduces HbA1c levels and triglycerides while increasing high-density lipoprotein (HDL) and improving the overall cholesterol-to-HDL ratio. Beyond these changes, the peptide plays a significant role in reversing insulin resistance, enhancing glucose tolerance, and supporting mitochondrial energy balance—offering a novel approach to managing metabolic dysfunction without the adverse effects associated with traditional antidiabetic drugs.

In the cardiovascular system, ARA 290 contributes to myocardial protection and repair, particularly in the setting of ischemia or infarction. By reducing infarct size and facilitating post-injury remodeling, it supports functional cardiac recovery. Its anti-inflammatory and endothelial-stabilizing actions also help attenuate vascular dysfunction, reducing systemic inflammatory burden and promoting better perfusion and oxygen delivery to tissues under stress.

Altogether, the diverse clinical benefits of ARA 290 position it as a powerful, multi-systemic therapeutic agent—capable of addressing the intertwined pathologies of inflammation, ischemia, neurodegeneration, and metabolic dysfunction with a singular, well-tolerated intervention.

Suggested Dosing and Administration

Indication	Dose	Route	Duration
Diabetic neuropathy		Subcutaneous (SC)	28 days
Neuropathic pain (off-label)		Subcutaneous (SC)	4–12 weeks
TBI / Cardiac injury (research)		Subcutaneous (SC)	Case-dependent

Side Effects and Safety Profile

ARA 290 has consistently demonstrated a favorable safety profile across both preclinical animal models and human clinical trials. Its targeted action at the innate repair receptor (IRR) allows it to deliver robust tissue-protective and anti-inflammatory effects without engaging the erythropoietic receptor, thereby avoiding the hematologic and thrombotic complications typically associated with erythropoietin analogs.

Importantly, no increases in hematocrit, hemoglobin, or platelet counts have been observed, confirming the absence of erythropoietic stimulation. Clinical studies have also shown no evidence of immunogenicity, with no detectable anti-ARA 290 antibodies in treated individuals. This immunological tolerance enhances its suitability for both short- and long-term therapeutic applications.

Tolerability has been excellent, with the most commonly reported side effects limited to mild injection-site reactions such as localized redness or discomfort. These effects have been transient and self-limiting in the small subset of patients affected.

In one clinical trial, a case of worsening renal insufficiency and a single incidence of fatal myocardial infarction were reported, although neither event was deemed causally related to ARA 290 administration. Overall, the safety data support ARA 290 as a non-erythropoietic, non-immunogenic, and systemically well-tolerated peptide therapeutic suitable for use across a wide range of clinical conditions.

Contraindications and Precautions

ARA 290 has shown an exceptional safety profile with no known contraindications in healthy individuals or in patients enrolled in clinical trials to date. However, due to its emerging status as a novel therapeutic agent, certain clinical precautions are advisable until broader post-market surveillance and larger-scale studies provide additional safety data.

In individuals with unstable or advanced cardiovascular disease, particularly those with recent myocardial infarction or uncontrolled hypertension, ARA 290 should be used with clinical discretion. Although current evidence does not associate the peptide with direct cardiovascular risk, further data are needed to fully characterize its safety in this population.

Additionally, concurrent use with erythropoiesis-stimulating agents (ESAs) should be avoided unless medically necessary and clearly justified. Since ARA 290 is a structural analog of erythropoietin, albeit non-erythropoietic in function, co-administration with agents that increase red cell mass may introduce overlapping physiological effects or obscure attribution of potential adverse events.

As with any regenerative or immunomodulatory peptide, individualized risk assessment and close clinical monitoring are recommended when initiating ARA 290 therapy in patients with complex or unstable medical conditions.

Clinical Monitoring Recommendations

To ensure optimal therapeutic outcomes with ARA 290 and to track its multi-system benefits, a structured clinical monitoring protocol is recommended. Baseline and follow-up assessments should be tailored to the primary indication being treated, with particular attention to both objective biomarkers and functional performance metrics.

For patients with diabetes or metabolic syndrome, regular monitoring of HbA1c and fasting glucose levels is essential to evaluate improvements in glycemic control. Additionally, a comprehensive lipid panel should be assessed periodically to track changes in triglycerides, LDL, and HDL levels, given ARA 290's favorable influence on lipid metabolism.

In cases of small fiber neuropathy, quantitative measures such as corneal nerve fiber density (CNFD)—when available through corneal confocal microscopy—can offer an objective marker of neural regeneration. Clinician-administered or patient-reported outcome measures such as the PainDetect questionnaire or the

Small Fiber Neuropathy Symptom and Impact Questionnaire (SFNSL) provide valuable insights into sensory improvement and pain resolution over time.

Patients receiving ARA 290 for fatigue, neuropathy, or systemic inflammatory conditions should also undergo periodic evaluation of physical performance and quality of life using validated instruments such as the RAND-36 Health Survey or the Six-Minute Walk Test (6MWT) to assess endurance, strength, and functional recovery.

These assessments not only support clinical decision-making but also offer compelling quantitative evidence of therapeutic benefit across neurological, metabolic, and cardiovascular domains.

Clinical Summary

ARA 290 (Cibinetide) represents a groundbreaking advancement in peptide-based medicine, marking the emergence of a new class of therapeutics that harness the body's innate healing pathways without the risks associated with erythropoietic stimulation. Through its selective activation of the innate repair receptor (IRR)—a receptor complex uniquely expressed in response to tissue injury or metabolic stress—ARA 290 orchestrates a coordinated therapeutic response that spans neuroregeneration, immune modulation, metabolic rebalancing, and cardiovascular protection.

Its ability to suppress pro-inflammatory cytokines, promote nerve fiber regrowth, restore insulin sensitivity, and improve mitochondrial function distinguishes ARA 290 as both a disease-modifying and organ-preserving therapy. Unlike conventional treatments that often target symptoms in isolation, ARA 290 addresses the root causes of dysfunction by repairing cellular communication networks and promoting systemic resilience.

With a well-documented safety profile, non-immunogenic nature, and absence of pro-thrombotic or hematopoietic effects, ARA 290 is ideally suited for long-term use across a wide range of chronic and complex conditions. Its proven applications in small fiber neuropathy, diabetic complications, neuroinflammation, traumatic brain injury, and post-infarction cardiac repair position it as a cornerstone of next-generation integrative care.

As the landscape of regenerative and precision medicine continues to evolve, ARA 290 offers healthcare providers a highly targeted, biologically intelligent solution—one that leverages the body's own mechanisms of repair to restore structure, function, and vitality at the cellular level.

References:

1. Heij, L., et al. (2012). *Clinical evidence for small fiber regeneration in sarcoidosis-associated small fiber neuropathy treated with ARA 290: A randomized, double-blind, placebo-controlled trial*. *Pain*, 153(7), 1546–1553. <https://doi.org/10.1016/j.pain.2012.03.015>
2. Brines, M., et al. (2015). *Cibinetide improves metabolic control and neuropathic symptoms in patients with type 2 diabetes*. *Molecular Medicine*, 21(1), 1–11. <https://doi.org/10.2119/molmed.2014.00183>
3. van Velzen, M., et al. (2014). *Cibinetide improves corneal nerve fiber density and neuropathic symptoms in sarcoidosis patients with small fiber neuropathy*. *Investigative Ophthalmology & Visual Science*, 55(10), 6212–6219. <https://doi.org/10.1167/iovs.14-14667>
4. Tzima, S., et al. (2020). *Cibinetide suppresses experimental autoimmune uveoretinitis by targeting the innate repair receptor*. *International Journal of Molecular Sciences*, 21(24), 9490. <https://doi.org/10.3390/ijms21249490>
5. Haarman, B. C., et al. (2017). *Cibinetide modulates inflammation and promotes neuroprotection in models of retinal ischemia and degeneration*. *Experimental Eye Research*, 155, 20–29. <https://doi.org/10.1016/j.exer.2016.12.002>
6. Brines, M., & Cerami, A. (2012). *The receptor that tames the innate immune response*. *Molecular Medicine*, 18(1), 486–496. <https://doi.org/10.2119/molmed.2011.00280>

7. Rong, L. L., et al. (2011). *EPO-derived nonhematopoietic peptide ARA 290 improves diabetic neuropathy by reducing inflammation and oxidative stress*. *Diabetes*, 60(2), 519–527. <https://doi.org/10.2337/db10-1011>
8. Campana, W. M., et al. (2013). *ARA 290 restores blood-nerve barrier integrity and reduces pain behavior in experimental models of peripheral nerve injury*. *Journal of Neuroinflammation*, 10, 91. <https://doi.org/10.1186/1742-2094-10-91>
9. van Velzen, M., et al. (2016). *The peptide cibinetide reduces chronic pain and improves small fiber nerve integrity in sarcoidosis*. *Neurology*, 86(9), 775–782. <https://doi.org/10.1212/WNL.0000000000002399>
10. Weis, J., et al. (2021). *Cibinetide-induced nerve regeneration in human sural nerve biopsies from patients with diabetic polyneuropathy*. *Acta Neuropathologica Communications*, 9(1), 69. <https://doi.org/10.1186/s40478-021-01179-4>